Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE M MANDRY

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1386674794
CMS profile
1228282
Location
OCOEE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,184.98

96 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,184.98 96

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE M MANDRY

NPI 1386674794 · CMS profile ID 1228282

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

OCOEE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386674794?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE M MANDRY, NPI 1386674794, CMS profile ID 1228282. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386674794?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOSE M MANDRY, NPI 1386674794, CMS profile ID 1228282. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386674794?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOSE M MANDRY, NPI 1386674794, CMS profile ID 1228282, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–96 of 96 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1386674794?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

96 matching records · $2,184.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 96 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–96 of 96.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $15.2306/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825460383 CMS
Clarus Therapeutics Inc. $19.8306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855024525 CMS
Esperion Therapeutics, Inc. $17.5206/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838348039 CMS
Corcept Therapeutics $19.2906/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837526543 CMS
Lilly USA, LLC $23.7105/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818567843 CMS
Acerus Pharmaceuticals Corporation $11.6205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777476257 CMS
SANOFI-AVENTIS U.S. LLC $14.5105/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843437669 CMS
Novo Nordisk Inc $19.7805/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810740051 CMS
Xeris Pharmaceuticals, Inc. $21.2805/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837433677 CMS
Esperion Therapeutics, Inc. $18.9105/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838348035 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.5905/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850106109 CMS
Radius Health, Inc. $15.7105/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830730013 CMS
Lilly USA, LLC $20.8005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819176921 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.6405/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763325948 CMS
Lilly USA, LLC $20.8005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 860805597 CMS
Merck Sharp & Dohme Corporation $15.1605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848595295 CMS
SANOFI-AVENTIS U.S. LLC $15.9704/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843437657 CMS
Esperion Therapeutics, Inc. $21.0104/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838348031 CMS
Novo Nordisk Inc $14.8704/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811673419 CMS
Lilly USA, LLC $25.2104/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818550969 CMS
Novo Nordisk Inc $15.7404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810896827 CMS
AbbVie Inc. $23.5304/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795476675 CMS
Clarus Therapeutics Inc. $97.2204/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855011979 CMS
Clarus Therapeutics Inc. $20.5703/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855018049 CMS
Xeris Pharmaceuticals, Inc. $18.1503/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837433672 CMS
DEXCOM, INC. $22.3503/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845287655 CMS
Horizon Therapeutics plc $14.9003/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797170089 CMS
Amneal Pharmaceuticals LLC $17.0503/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667803 CMS
Radius Health, Inc. $19.2403/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830729931 CMS
SANOFI-AVENTIS U.S. LLC $20.1303/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843437639 CMS
Clarus Therapeutics Inc. $27.7803/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855011977 CMS
Radius Health, Inc. $56.5503/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830730045 CMS
Medtronic, Inc. $18.7402/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815589241 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.2402/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849941683 CMS
Esperion Therapeutics, Inc. $125.0101/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838348027 CMS
Merck Sharp & Dohme Corporation $13.8901/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848665055 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.4101/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763325950 CMS
SANOFI-AVENTIS U.S. LLC $16.5001/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843437623 CMS
Esperion Therapeutics, Inc. $14.4101/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838348025 CMS
Novo Nordisk Inc $13.4201/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811099819 CMS
Radius Health, Inc. $20.5701/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830729867 CMS
Clarus Therapeutics Inc. $23.0701/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855013919 CMS
Lilly USA, LLC $21.1101/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818567841 CMS
Medtronic, Inc. $17.9601/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815565143 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.3301/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820064801 CMS
Amarin Pharma Inc. $15.9201/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815043981 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,709.18 114
PY2020 $1,853.36 83
PY2021 $2,184.98 96
PY2022 $2,614.56 105
PY2023 $3,679.56 93
PY2024 $5,949.36 89
PY2025 $3,527.20 89

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,273,594.71 217
PY2024 Recipient $7,650.00 2
PY2024 Principal investigator $1,929,839.01 45
PY2023 Recipient $1,643.36 3
PY2023 Principal investigator $1,240,388.68 21
PY2022 Recipient $19,696.00 2
PY2022 Principal investigator $1,074,907.09 26
PY2021 Recipient $32,405.69 3
PY2021 Principal investigator $993,908.28 94
PY2020 Principal investigator $839,923.61 73
PY2019 Recipient $1,197.13 12
PY2019 Principal investigator $767,020.79 63

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

217 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,784.00 12/31/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202533649
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700038
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 12/17/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700212
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 12/17/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700214
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 12/17/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700216
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 12/17/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220700226
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 12/17/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220700228
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,622.00 12/10/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803890
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,865.00 12/05/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803922
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $47.71 12/02/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220803924
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700028
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 12/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700210
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700030
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700032
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 11/19/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700034
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 11/19/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700036
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,666.00 11/13/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803888
Principal investigator 1 ABBVIE INC. $54,397.20 11/05/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522593
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700206
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 11/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700208
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 10/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220700220
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 10/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220700222
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220700224
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,454.00 10/21/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803886
Principal investigator 1 ABBVIE INC. $34,629.40 10/09/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202515575
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 10/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700202
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700204
Principal investigator 1 Boehringer Ingelheim International GmbH $46.88 10/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220700218
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700026
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700200
Principal investigator 1 ABBVIE INC. $57,184.40 09/04/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509146
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 09/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700166
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700184
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803878
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803880
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803882
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803884
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 08/26/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700022
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 08/26/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700024
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 08/26/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700192
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 08/26/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700194
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 08/26/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700196
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 08/26/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700198
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,386.00 08/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803876
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803910
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803912
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803914
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803916
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803918
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 08/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803920
Principal investigator 1 Eli Lilly and Company $2,343.21 08/12/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187893894
Principal investigator 1 ABBVIE INC. $58,068.40 08/06/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502775
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 08/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700178
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700182
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,188.00 08/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803874
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700012
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700014
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700016
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700018
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700020
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700186
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700188
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 07/28/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700190
Principal investigator 1 AstraZeneca Pharmaceuticals LP $57,014.77 07/25/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185550849
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,400.00 07/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803872
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $594.00 07/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803870
Principal investigator 1 PFIZER INC. $10,000.00 07/18/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCEDAILY ORAL DANUGLIPRON IN ADULTS WITH OVERWEIGHT OR OBESITY No dispute reported 06/30/2026 1228772525
Principal investigator 1 Eli Lilly and Company $483,265.00 07/15/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187891804
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,254.00 07/09/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803866
Principal investigator 1 ABBVIE INC. $27,084.20 07/02/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495573
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700004
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700006
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700008
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700010
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700168
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700170
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700172
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700174
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700176
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700180
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,502.00 06/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803864
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699994
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699996
Principal investigator 1 Boehringer Ingelheim International GmbH $985.50 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699998
Principal investigator 1 Boehringer Ingelheim International GmbH $38.28 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700000
Principal investigator 1 Boehringer Ingelheim International GmbH $49.68 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220700002
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700156
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700158
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700160
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 06/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700162
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,180.00 06/12/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803906
Principal investigator 1 Amgen Inc. $131,551.07 06/08/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY, PA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246652116
Principal investigator 1 ABBVIE INC. $110,398.60 06/03/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487343
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699980
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699982
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699984
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699986
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700128
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700130
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700132
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700134
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700136
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700138
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700140
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700142
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 06/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700164
Principal investigator 1 Boehringer Ingelheim International GmbH $221.54 05/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699992
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 05/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700154
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $180.00 05/12/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803868
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $180.00 05/12/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803908
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,063.00 05/09/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803862
Principal investigator 1 ABBVIE INC. $56,739.80 05/07/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482957
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $225.81 05/06/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803904
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $14,782.00 05/06/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187891560
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,111.00 05/05/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803902
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699972
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699974
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699976
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699978
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700114
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700116
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700118
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700120
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700122
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700124
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 05/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700126
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,225.00 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225403467
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699988
Principal investigator 1 Boehringer Ingelheim International GmbH $530.64 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699990
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700144
Principal investigator 1 Boehringer Ingelheim International GmbH $839.50 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700146
Principal investigator 1 Boehringer Ingelheim International GmbH $530.64 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700148
Principal investigator 1 Boehringer Ingelheim International GmbH $33.06 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700150
Principal investigator 1 Boehringer Ingelheim International GmbH $28.98 04/23/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700152
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,167.00 04/11/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803858
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,100.00 04/11/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803900
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 04/10/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803860
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,946.15 04/04/2025 Non-covered Recipient Entity
DIABETES AND ENDOCRINOLOGY ASSOCIATES OF STARK COUNTY, INC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185550839
Principal investigator 1 ABBVIE INC. $39,806.00 04/03/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202469947
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699964
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699966
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699968
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699970
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700096
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700098
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700100
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700102
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700104
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700106
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700108
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 04/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700112
Principal investigator 1 Boehringer Ingelheim International GmbH $163.24 03/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700080
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700082
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700084
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 03/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700086
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 03/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700088
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 03/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700090
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,066.00 03/24/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803856
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,500.00 03/19/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185550843
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,450.00 03/19/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes No dispute reported 06/30/2026 1225402729
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,806.00 03/13/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803898
Principal investigator 1 ABBVIE INC. $24,904.10 03/07/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459735
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699948
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699950
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699952
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699954
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700060
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700062
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700064
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700066
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700068
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700070
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700072
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 02/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699962
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700074
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 02/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700076
Principal investigator 1 Boehringer Ingelheim International GmbH $8.28 02/25/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700078
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,612.00 02/20/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803896
Principal investigator 1 Eli Lilly and Company $17,160.00 02/18/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187893892
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,062.00 02/13/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803854
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,732.00 02/11/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803894
Principal investigator 1 ABBVIE INC. $51,030.20 02/06/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448482
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699940
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699942
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699944
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699946
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700048
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700050
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700052
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700054
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700056
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700058
Principal investigator 1 Eli Lilly and Company $2,580.33 01/31/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187893180
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699956
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 01/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699958
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 01/27/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699960
Principal investigator 1 Eli Lilly and Company $262.00 01/23/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187891558
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,242.71 01/22/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY
TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal No dispute reported 06/30/2026 1185550847
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $930.00 01/22/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225411794
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,434.00 01/22/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220803892
Principal investigator 1 Eli Lilly and Company $35,412.00 01/21/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187893798
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,298.00 01/17/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220803852
Principal investigator 1 Eli Lilly and Company $1,007.25 01/13/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187893182
Principal investigator 1 AstraZeneca Pharmaceuticals LP $89,982.95 01/08/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185550845
Principal investigator 1 Eli Lilly and Company $145,355.69 01/07/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY PA
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187893328
Principal investigator 1 AstraZeneca Pharmaceuticals LP $426,052.90 01/03/2025 Non-covered Recipient Entity
WEST ORANGE ENDOCRINOLOGY
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185550841
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699932
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699934
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699936
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220699938
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700040
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700042
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700044
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700046
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700092
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700094
Principal investigator 1 Boehringer Ingelheim International GmbH $273.67 01/01/2025 Non-covered Recipient Entity
West Orange Endocrinology PA
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220700110